BE547257A - - Google Patents
Info
- Publication number
- BE547257A BE547257A BE547257DA BE547257A BE 547257 A BE547257 A BE 547257A BE 547257D A BE547257D A BE 547257DA BE 547257 A BE547257 A BE 547257A
- Authority
- BE
- Belgium
- Prior art keywords
- aluminum phosphate
- suspension
- product
- sep
- poliomyelitis
- Prior art date
Links
- 239000000047 product Substances 0.000 claims description 110
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 82
- 239000000427 antigen Substances 0.000 claims description 67
- 239000000725 suspension Substances 0.000 claims description 63
- 208000000474 Poliomyelitis Diseases 0.000 claims description 62
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 241000700605 Viruses Species 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 33
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 31
- 229960001950 benzethonium chloride Drugs 0.000 claims description 31
- 238000002255 vaccination Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- 239000012736 aqueous medium Substances 0.000 claims description 19
- 239000002244 precipitate Substances 0.000 claims description 18
- 229960001539 poliomyelitis vaccine Drugs 0.000 claims description 17
- 238000001179 sorption measurement Methods 0.000 claims description 17
- 229910052782 aluminium Inorganic materials 0.000 claims description 16
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002504 physiological saline solution Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 241000991587 Enterovirus C Species 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 3
- 208000003926 Myelitis Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 83
- 230000036515 potency Effects 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 15
- 241000282693 Cercopithecidae Species 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 239000013068 control sample Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000010908 decantation Methods 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229960003872 benzethonium Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940001496 tribasic sodium phosphate Drugs 0.000 description 2
- 229910017119 AlPO Inorganic materials 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 101100388690 Plasmodium falciparum (isolate K1 / Thailand) MEF-1 gene Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- -1 i.e. Proteins 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE547257A true BE547257A (cg-RX-API-DMAC10.html) |
Family
ID=174291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE547257D BE547257A (cg-RX-API-DMAC10.html) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE547257A (cg-RX-API-DMAC10.html) |
-
0
- BE BE547257D patent/BE547257A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109666685B (zh) | Hpv卵黄抗体及其在制备治疗hpv感染的药物的应用 | |
| JPH0313205B2 (cg-RX-API-DMAC10.html) | ||
| JPS58500948A (ja) | 「う」蝕症からの保護 | |
| JP3977257B2 (ja) | 混合ワクチンの製造方法 | |
| EP0007467A1 (fr) | Vaccin antigrippal et procédé pour sa préparation | |
| KR20150080643A (ko) | Ｉｐｖ―ｄｐｔ 백신 | |
| FR2483779A1 (fr) | Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins | |
| BE547257A (cg-RX-API-DMAC10.html) | ||
| FR2499410A1 (fr) | Vaccin contre l'avortement enzootique chez les brebis et son procede de preparation | |
| PL156487B1 (pl) | Sposób prowadzenia hodowli Treponema hyodysenteriae PL PL PL | |
| BE669872A (fr) | substances à activité biologique | |
| US3147185A (en) | Process for purifying viral substances and composition | |
| CN112641936B (zh) | 一种鹅星状病毒纤突蛋白脂质体疫苗及其制备方法和应用 | |
| FR2481927A1 (fr) | Composition anti-allergique et son procede de preparation a partir d'une bacterie lactique du genre streptococcus | |
| CN116926098B (zh) | 增强t7 rnap对胶原蛋白/弹力蛋白转录活性的定向进化系统和方法 | |
| FR2646778A1 (fr) | Suspensions de cellules memoire immunitaires et leur procede de preparation | |
| CN117397732B (zh) | 一种发酵乳乳清产品及其制备方法 | |
| CN118813478A (zh) | 一种副猪嗜血杆菌外膜囊泡及其疫苗、制备方法与应用 | |
| FR2731162A1 (fr) | Procede d'extraction d'au moins un actif a partir de cellules vegetales indifferenciees | |
| JPS59500615A (ja) | ナイザ−淋菌ワクチン | |
| BE539861A (cg-RX-API-DMAC10.html) | ||
| CN116831928A (zh) | 一种含天然冰片的抑制痤疮丙酸杆菌组合物及其在化妆品中的应用 | |
| BE567849A (cg-RX-API-DMAC10.html) | ||
| CH631078A5 (en) | Acellular vaccine | |
| WO1993012815A1 (fr) | Procede d'obtention d'un antigene de surface recombine de l'hepatite b, antigene et vaccin a base de celui-ci |